We examined sequential serum samples from 12 patients with well-characterized posttransfusion non-A, non-B hepatitis who had an acute, resolving self-limited type of clinical course for the presence of antibody to the hepatitis C virus nucleocapsid (core) protein (p22) expressed by a recombinant bac
Improved diagnosis of chronic hepatitis C virus infection by detection of antibody to multiple epitopes: Confirmation by antibody to synthetic oligopeptides
✍ Scribed by D. Brown; L. Powell; A. Morris; S. Rassam; S. Sherlock; N. McIntyre; A. J. Zuckerman; Dr. G. M. Dusheiko
- Publisher
- John Wiley and Sons
- Year
- 1992
- Tongue
- English
- Weight
- 499 KB
- Volume
- 38
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Serum samples from 226 patients covering a wide spectrum of liver disease were tested for antibodies to hepatitis C virus (HCV) using both first and second generation enzyme linked immunosorbent assays. Selected sera were also tested by peptide immunoassays, by the four‐antigen recombinant immunoblot assay (RIBA II), and for viral genome by the polymerase chain reaction. Antibody to c100‐3 was detected in 61% of patients with chronic non‐A, non‐B (NANB) hepatitis and/or 46.5% with presumed NANB‐related cirrhosis by the first generation test. These figures increased to 77% and 58% when antibodies to recombinant structural and non‐structural HCV antigens were sought by the second generation assay. Supplemental testing against peptide Sp75 and Sp65isp67 confirmed that reactivity of sera by second generation assays was due to antibodies t o the additional structural and non‐structural antigens. Samples negative by the first generation assay were not confirmed by the supplemental assay using peptides Sp75 and Sp65/Sp67. HCV RNA was detected in 60% of the anti‐HCV positive sera tested, most of which were also RIBA II positive. Our findings confirm that the introduction of the structural and non‐structural antigens, especially the putativenucleocapsid protein, improves sensitivity of detection of antibodies to HCV, and facilitates diagnosis in patients with “cryptogenic” chronic hepatitis. © 1992 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract Fifty‐seven sera with indeterminate results by the second generation RIBA (RIBA 2) for confirmation of hepatitis C virus (HCV) enzyme linked immunoassay (ELISA) reactivity were tested by the new third generation RIBA (RIBA 3). Thirty three (57.9%) displayed reactivity for at least one o
To clarify the relationship between hepatitis C virus infection and the development of hepatocellular carcinoma as sequelae of non-A, non-B posttransfusion hepatitis, 231 patients with chronic non-A, non-B hepatitis (96 with chronic hepatitis, 81 with cirrhosis and 64 with hepatocellular carcinoma)
A panel of 16 type-specific synthetic peptides corresponding to variable antigenic regions within the hepatitis C virus (HCV) core, nonstruc-tural4 (NS4), and NS5 proteins was synthesised. The peptide panel was used to develop an enzyme immunoassay (EIA) for the detection of antibodies directed to H
Serum samples from 103 blood donors or patients with slightly increased serum levels of liver enzymes were tested for antibodies to hepatitis C virus (anti-HCV) using second generation tests and for HCV RNA by the polymerase chain reaction (PCR). PCR was in a nested configuration, using primer pairs